Lymphoma Research Foundation to Honor Longtime Foundation Supporter and Past Board Chair Steven J. Prince […] The post Lymphoma Research Foundation to Honor Longtime Foundation Supporter and Past Board Chair Steven J. Prince at Annual Gala on September 25  appeared first on Lymphoma Research Foundation ..read more

The Lymphoma Research Foundation – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – today announced the election of Kristi Hendriks of Boston, MA to its Board of Directors.   The post Lymphoma Research Foundation Elects Kristi Hendriks to Esteemed Board of Directors  appeared first on Lymphoma Research Foundation ..read more

Latest News Home » News Lymphoma Research Foundation Elects New Scientific Advisory Board Members Foundation welcomes four world-leading lymphoma experts to contribute to the global impact of the Foundation and guide the Foundation’s research portfolio The Lymphoma Research Foundation is proud to welcome four new members to its elite Scientific Advisory Board (SAB): Alex Herrera, MD Chief, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope Kami Maddocks, MD Lymphoma Program Director The Ohio State University Todd Fehniger, MD, PhD Professor of ..read more

Latest News Home » News On June 26, 2024, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.  Epcoritamab-bysp (Epkinly, Genmab US, Inc.) is a bispecific antibody. Bispecific antibodies are engineered hybrid molecules with two unique binding domains, each of which recognizes a certain target, unlike monoclonal antibodies that have two arms that both recognize the same target ..read more

Latest News Home » News Donor Spotlight: Leigh Olson Leigh Olson’s experience with the Lymphoma Research Foundation started in a doctor’s waiting room. It was 1999, and she was in Northwestern Memorial Hospital in Chicago with her father for his first appointment after being diagnosed with diffuse large B-cell lymphoma (DLBCL). At the time, Leigh knew little about the disease, treatment options, or the potential outcomes. But there in the waiting room was a pamphlet from the Cure for Lymphoma organization (which later became the Lymphoma Research Foundation). It’s what introduced her to th ..read more

Latest News Home » News Conquering the Unknowns in Lymphoma Henry Stanley Plummer, one of the founders of the Mayo Clinic, once wrote, “What is research? It is nothing more or less than trying to find out the things that are unknown. When you are not doing that, and you think you are doing research, you are not.” This quote has echoed throughout Dr. Thomas Habermann’s research career for decades and has helped him stay focused on the art of discovery. As the first Chair of the Mayo Clinic’s Lymphoma Group, the former Chair of the Lymphoma Research Foundation’s Scientific Advisory Board (SA ..read more

Latest News Home » News Where Are They Now? Lymphoma Rounds 15 Years In Review The Lymphoma Research Foundation’s disease specificity and hyper-focus on finding cures for every type of lymphoma ensure the next generation of cancer researchers dedicate their careers to studying lymphoma and world-leading lymphoma experts collaborate and accelerate the pace of scientific discovery. In 2008, the Lymphoma Research Foundation expanded its first-in-class lymphoma education programming and developed Lymphoma Rounds. Lymphoma Rounds programs provide a forum for healthcare professionals to meet r ..read more

Latest News Home » News Tackling Obstacles On and Off the Field In many ways, Timmy Ward is a typical college senior, majoring in sociology and playing football for the Rutgers Scarlet Knights – a Big Ten powerhouse. However, what most people don’t know is what he has had to overcome to get here. Growing up in Pennsylvania, Timmy was always a talented athlete who excelled in sports. In high school, he participated in football, wrestling, track, and baseball before concentrating on football and wrestling to pursue his lifelong dream of playing college football. Everything was going accordin ..read more

Latest News Home » News Meet the 2024 Career Development Award and Postdoctoral Fellowship Research Grantees The Lymphoma Research Foundation announced its 2024 grant class – 28 research grants awarded to scientists based at many of the world’s leading cancer research institutions – totaling more than $3.5 million in innovative lymphoma and chronic lymphocytic leukemia (CLL) research. The 2024 grantee class encompasses 18 medical and academic institutions, with research initiatives investigating several lymphoma subtypes, genetic mechanisms, and emerging therapeutic methods. The grant selec ..read more

Latest News Home » News On May 30, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received two or more prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi). Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) is a form of CAR T cell therapy. CAR T cell therapy provides engineered molecules called chimeric antigen receptors (CARs) that recognize and destroy antigens present on the surface ..read more